MHMengting Hu

Mengting Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengting Hu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bidirectional Mendelian randomization and colocalization analysis of gut microbiota on lipid profile

    by Yu Cui, Yanzhu Chen, Mengting Hu, He Zhou, Jiarui Guo, Qijia Wang, Zaihua Xu, Liyun Chen, Wancong Zhang, Shijie Tang


  • Open Access

    Genome-wide Mendelian Randomization Identifies Potential Drug Targets for Dorsopathies

    by Yu Cui, Jiarui Guo, Yuanxi Lu, Mengting Hu, He Zhou, Wancong Zhang, Shijie Tang

    Background: Dorsopathies are a group of musculoskeletal disorders affecting the spinal column and related structures, contributing significantly to global disability rates and healthcare costs. Despite their prevalence, the genetic and biological mechanisms underlying dorsopathies are not fully understood. Method: Summary-data-based Mendelian Randomization (SMR) and colocalization analysis were employed, using data from genome-wide association studies (GWAS) and cis-expression quantitative trait loci (cis-eQTLs) databases. Genes with a colocalization posterior probability (PP.H4) above 0.7 in SMR results were selected for additional analysis. These selected genes underwent MR analysis to examine possible causal connections with dorsopathies, and sensitivity analyses were carried out to ensure robustness. Additionally, two transcriptome-wide association studies (TWAS) were utilized to confirm and screen for potential drug targets. Result: We identified four essential genes linked to dorsopathies: NLRC4 , CGREF1 , KHK , and RNF212 . Mendelian randomization (MR) analysis revealed a potential causal link between these genes and dorsopathies. Elevated transcription levels of NLRC4 , CGREF1 , and KHK correlated with reduced dorsopathies risk, while increased levels of RNF212 were associated with heightened risk of dorsopathies. Regarding methylation sites, an increase in cg04686953 fully mediated the decreased risk of dorsopathies by RNF212 . Similarly, the risk effect of cg26638505 and cg18948125 was entirely mediated by NLRC4 , while CGREF1 predominantly mediated the risk-increasing effect of cg06112415 and the decrease effect of cg22740783 . Conclusion: Dorsopathies were associated with four pivotal genes: NLRC4 , CGREF1 , KHK , and RNF212 . Methylation analysis identified cg04686953 and cg22740783 as protective against dorsopathies risk, while cg26638505 , cg18948125 , and cg06112415 exhibited a risk-increasing impact.

  • Open Access

    Identifying Potential Drug Targets for Varicose Veins through Integration of GWAS and eQTL Summary Data

    by Yu Cui, Mengting Hu, He Zhou, Jiarui Guo, Qijia Wang, Zaihua Xu, Liyun Chen, Wancong Zhang, Shijie Tang

    Background: Varicose veins (VV) is a common chronic venous disease that is influenced by multiple factors. It affects the quality of life of patients and imposes a huge economic burden on the healthcare system. This study aimed to use integrated analysis methods, including Mendelian randomization analysis, to identify potential pathogenic genes and drug targets for VV treatment. Methods: This study conducted summary-data-based Mendelian randomization (SMR) analysis and colocalization analysis on data collected from genome-wide association studies (GWASs) and cis-expression quantitative trait loci (cis-eQTL) databases. Only genes with PP. H4 > 0.7 were chosen from the significant SMR results. After the above analysis, we screened 12 genes and performed Mendelian Randomization analysis on them. After sensitivity analysis, we identified four genes with potential causal relationships with VV. Finally, we used transcriptome-wide association studies (TWAS) analysis and The Drug-Gene Interaction Database (DGIdb, https://dgidb.org )data to identify and screen the remaining genes and identified four drug targets for the treatment of VV. Results: We identified four genes significantly associated with VV, namely KRTAP5-AS1 (OR = 1.08, 95% CI: 1.05−1.11, p = 1.42e−10) and PLEKHA5 (OR = 1.13, 95% CI: 1.06-1.20, p = 6.90e−5), CBWD1 (OR = 1.05, 95% CI: 1.01-1.11, p = 1.42e−2) and CRIM1 (OR = 0.87, 95% CI: 0.81-0.95, p = 3.67e−3). Increased expression of three genes, namely KRTAP5-AS1 , PLEKHA5 , and CBWD1 , was associated with increased risk of the disease, and increased expression of CRIM1 was associated with decreased risk of the disease. These four genes could be targeted for VV therapy. Conclusion: This study identified four drug targets for potential treatment of VV, and the results may contribute to improving the quality of life of VV patients.